Build an AI swarm drone with Python, Crazyflie 2.1, Whisper voice control, and object detection for manual, autonomous flight ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in UnitedHealth Group Inc (Symbol: UNH), where a total volume of 92,988 contracts has ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Learn how to build a perceptron from scratch in Python! This tutorial covers the theory, coding, and practical examples, helping you understand the foundations of neural networks and machine learning.

Learn how backpropagation works by building it from scratch in Python! This tutorial explains the math, logic, and coding behind training a neural network, helping you truly understand how deep ...

Replimune received a complete response letter from the FDA, denying accelerated approval for RP1 plus Opdivo in advanced melanoma for now. The FDA cited issues with the IGNYTE trial design and patient ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...